Intercellular adhesion molecule 1 (ICAM-1) is believed to be involved in metastasis of hepatocellular carcinoma (HCC) cells. Cancer stem cells promote tumor relapse and metastasis. We investigated whether ICAM-1 is a marker of HCC stem cells. METH-ODS: Sphere formation and tumor formation assays were performed to investigate the stem cell properties of ICAM-1 ϩ cells in vitro and in vivo. A specific targeting system that inhibits ICAM-1 expression and hepatitis B virus transgenic mice (M-TgHBV) were used to investigate whether inhibition of ICAM-1 reduced tumor incidence and metastasis in vivo. We used real-time polymerase chain reaction and immunoblot analysis to assess ICAM-1 and Nanog expression in tumor cell lines, and flow cytometry analysis was used to investigate ICAM-1 expression in HCC and blood samples. RESULTS: ICAM-1 was expressed on a minor cell population in HCC tumor cell lines, as well as in tumor tissues and circulating tumor cells isolated from patients and transgenic mice. ICAM-1 ϩ tumor cells had greater sphere-forming and tumorigenic capacities and increased expression of stemness-related genes compared with ICAM-1 Ϫ tumor cells. The specific inhibition of ICAM-1 reduced formation and metastasis in M-TgHBV mice. ICAM-1 was found to be a marker of circulating tumor cells from patients and M-TgHBV mice. Increased numbers of CD45 Ϫ ICAM-1 ϩ cells in blood samples of patients with HCC correlated with worse clinical outcomes. The stem cell transcription factor Nanog regulated expression of ICAM-1 in HCC stem cells. CON-CLUSIONS: ICAM-1 is a marker of HCC stem cells in humans and mice; ICAM-1 inhibitors slow tumor formation and metastasis in mice. ICAM-1 expression is regulated by the stem cell transcription factor Nanog.
H epatocellular carcinoma (HCC) is the 5th most common cancer in the world and accounts for more than 90% of human liver cancers. Hundreds of thousands of deaths result from HCC worldwide every year, and as many as 90% of these cancer-associated deaths are related to metastasis. 1 Intercellular adhesion molecule 1 (ICAM-1; CD54), a 90-kilodalton cell surface glycoprotein of the immunoglobulin superfamily, is believed to be responsible for HCC metastasis. 2 Previous studies have shown that ICAM-1 is expressed on hepatocytes in cancerous areas but not on hepatocytes in noncancerous areas. 3 The expression of ICAM-1 has been reported to mediate adhesion-dependent cell-cell interactions and facilitate the movement (or retention) of cells through the extracellular matrix, 4 -6 and it has been shown to be positively correlated with tumor size and poor prognosis in HCC. 7, 8 Recently, it was observed that ICAM-1 is expressed on stem cells, such as bone marrow mesenchymal stem cells, adipose stem cells, periodontal ligament stem cells, and placenta mesenchymal stem cells, 9 -12 in addition to endothelial cells and epithelial cells. 2 Based on these findings, ICAM-1 is now considered a mesenchymal stem cell and periodontal ligament stem cell marker. 12, 13 Although it is known that cancer stem cells (CSCs) have crucial roles in cancer relapse and metastasis, whether ICAM-1 is expressed on HCC CSCs remains unclear.
CSCs, a subset of cancer cells with features of stem cells such as self-renewal ability and pluripotency, are believed to be responsible for tumor relapse and metastasis. 14 -16 In HCC, CSCs were first defined as a side population. Haraguchi et al identified side population cells that possess stem cell properties such as self-renewal, pluripotency, and chemoresistance. 17 Recently, CSCs were characterized based on their expression of various surface molecules, such as CD133, CD90, EpCAM, and CD44. 18 -21 Using these cell surface molecules, HCC CSCs were sorted from HCC cell lines, tissues, and blood samples and found to be capable of self-renewal and tumor initiation and to be resistant to chemotherapeutic drugs. Experimental procedures targeting cells expressing CSC markers have been shown to reduce tumor incidence and metastasis in vivo, indicating that eliminating CSCs may be an efficient therapeutic strategy.
In the present study, we detected ICAM-1 expression in a minor cell population found in HCC tumor cell lines, tumor tissues, and circulating tumor cells. ICAM-1 ϩ tumor cells displayed enhanced sphere-forming and tumorigenic capacities and elevated expression of stemnessrelated genes, including Nanog and Oct4, compared with ICAM-1 Ϫ tumor cells. Moreover, the inhibition of ICAM-1 reduced tumor initiation and metastasis in vivo. Additionally, we found that Nanog transcribes ICAM-1 expression in CSCs. Based on these findings, we propose that ICAM-1 is a functional CSC surface marker in HCC that is regulated by the stem cell transcription factor Nanog.
Materials and Methods Samples
Human tumor tissues and blood samples were obtained from patients with HCC at the Eastern Hepatobiliary Surgery Hospital after obtaining informed consent. The follow-up procedures applied to these patients have been described in a previous report. 22 Overall survival and disease-free survival were defined as previously described. 23 Female nude mice (4 -6 weeks old) were purchased from the Transgenic Animal Research Center, Second Military Medical University. All mice were maintained in a pathogen-free facility and used in accordance with the institutional guidelines for animal care.
Quantitative Real-Time Polymerase Chain Reaction
Total RNA was isolated from cell lines and clinical samples with TRIzol reagent according to the manufacturer's protocol (Invitrogen, Carlsbad, CA). Reverse-transcription reactions were conducted with oligo(dT) 18 primers and random primers according to the instructions of the manufacturer of the M-MLV Reverse Transcriptase Kit (Invitrogen). Real-time polymerase chain reaction (PCR) was performed with SYBR Premix Ex Taq (Takara Bio Inc, Otsu Shiga, Japan) using the StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA). The primers used in these assays are listed in Supplementary Table 1 . The gene expression levels were calculated relative to the expression of ␤-actin in tumor cell lines or clinical samples using the 2 Ϫ⌬⌬Ct method.
Western Blot Analysis
The total soluble proteins (100 g) extracted from the samples were resolved in 10% sodium dodecyl sulfate/polyacrylamide gels and transferred electrophoretically to a polyvinylidene fluoride membrane. The blots were blocked with 5% skim milk and then incubated with primary antibodies (Supplementary Table 2 ). The blots were then incubated with an antirabbit secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and visualized by enhanced chemiluminescence.
Single-Cell Sorting
Single-cell suspensions were obtained from clinical samples by digesting tumor tissues with type IV collagenase (Gibco BRL, Grand Island, NY) for 1 to 3 hours at 37°C, followed by filtration through a 100-m cell strainer (BD Biosciences, San Jose, CA). To isolate ICAM-1 ϩ cell populations, single cells from cell lines or clinical samples were stained with a PE-conjugated ICAM-1 antibody (eBioscience, San Diego, CA) and with the corresponding isotype control. The samples were analyzed and sorted on a FACSAria cell sorter (BD Biosciences). The positive and negative populations were selected for the following experiments.
Flow Cytometric Analysis
The antibodies used in these analyses are listed in Supplementary Table 2 . The cells were incubated with the antibodies in phosphate-buffered saline containing 1% bovine serum albumin and 0.1% sodium azide. The corresponding isotype immunoglobulins were used as controls. The data were analyzed with a FACSCalibur flow cytometer and CellQuest software (BD Biosciences).
Chromatin Immunoprecipitation Assay
Cells were processed for chromatin immunoprecipitation (ChIP) assays using a chromatin immunoprecipitation assay kit (Millipore Corp, Billerica, MA) according to the manufacturer's protocol. Briefly, the cells were cross-linked with 1% formaldehyde for 10 minutes at 37°C and lysed with sodium dodecyl sulfate lysis buffer. The lysate pellets were sonicated with a sonic dismembrator (Fisher Scientific, Waltham, MA). Protein-DNA complexes were immunoprecipitated with the appropriate antibodies (Supplementary Table 2 ). The immunoprecipitates were dissolved in 20 L water for PCR analysis. Standard PCR amplifications were performed using Taq PCR Master Mix (Takara Bio Inc) with the specific primers listed in Supplementary Table 1 .
Statistical Analysis
Student t tests were used to compare 2 groups unless otherwise indicated ( 2 test). Categorical data were analyzed using Fisher exact test, and quantitative variables were analyzed using t tests or Pearson's correlation test. Survival was calculated with the log-rank test. The Cox regression model was used to perform multivariate analysis. P Ͻ .05 was considered statistically significant.
For a description of other materials and methods used in this study, see Supplementary Materials and Methods.
Results

ICAM-1 ؉ Tumor Cells Possess Characteristics of Stem/Progenitor Cells
To investigate whether ICAM-1 can be used as a CSC marker, we first determined whether an ICAM-1 ϩ cell population was present in tumor cell lines. Flow cytometry analysis showed that approximately 5% of Huh7 cells and 7% of Hep3B cells expressed ICAM-1 ( Figure 1A ). We next examined whether the ICAM-1 ϩ cells exhibited intrinsic properties of stem cells. For this purpose, ICAM-1 ϩ cells were isolated from tumor cell lines, and the expression of stemness-related genes, including sox2, nanog, oct4, and ␤-catenin, was assessed at the messenger RNA (mRNA) level. Compared with ICAM-1 Ϫ cells, ICAM-1 ϩ cells expressed higher levels of these 4 genes, of which ␤-catenin was increased the least ( Figure 1B To investigate the CSC properties of ICAM-1 ϩ cells in vitro, a sphere formation assay was performed. Isolated cells were cultured in serum-free epidermal growth factor/ basic fibroblast growth factor-supplemented medium. One week later, many hepatospheres were observed in cultures of ICAM-1 ϩ cells isolated from both Huh7 and Hep3B cells, whereas very few spheres formed in the ICAM-1 Ϫ cell cultures ( Figure 1C ). We next inoculated nude mice subcutaneously with ICAM-1 ϩ cells and ICAM-1 Ϫ cells to investigate their tumorigenicity in vivo. A significant difference in tumor incidence was observed between the mice inoculated with ICAM-1 ϩ cells and those inoculated with ICAM-1 Ϫ cells (Table 1) . Three months postinoculation, as few as 1000 ICAM-1 ϩ cells were sufficient to generate tumors in nude mice, whereas the ICAM-1 Ϫ cells did not induce tumor formation, even when 1 ϫ 10 4 cells were injected ( Figure 1D and Table 1 ). Histologic staining identified similar histologic features in tumor xenografts generated by ICAM-1 ϩ cells and those generated by total tumor cells ( Figure 1E ). Figure 1A) . In Hep3B cells, these markers were mostly expressed on ICAM-1 ϩ cells (Supplementary Figure 1B) .
Collectively, these results suggest that ICAM-1 ϩ cells display CSC properties.
Clinical Significance of ICAM-1 ؉ HCC Cells
Having shown that ICAM-1 ϩ cells derived from HCC cell lines possess CSC characteristics, we next investigated the role of ICAM-1 ϩ HCC cells in patients with HCC. Because ICAM-1 has been reported to be expressed in certain other cell types, such as endothelial cells, epithelial cells, and fibroblasts, 2 single-cell suspensions were first prepared using fresh HCC tumor tissues from patient 30 (P#30) and patient 50 (P#50) and cultured in vitro. HCC cells were harvested from these primary cultures, and the ICAM-1 expression pattern was then evaluated by flow cytometry. As shown in Figure 2A , the ICAM-1 ϩ cell subpopulations were found to represent less than 2% of the cultured primary HCC cells. The positive expression of cytokeratin 19 (K19) and ␣-fetoprotein (AFP) ensured that these ICAM-1 ϩ cells were HCC cells (Supplementary Figure 2) . To investigate the CSC characteristics of ICAM-1 ϩ tumor cells, a sphere formation assay was performed. As shown in Figure 2B (left panel), the ICAM-1 ϩ cells isolated from P#30 and P#50 showed higher sphereforming capacities than the ICAM-1 Ϫ cells from the same patients. Next, the properties of cells in the hepatospheres were further evaluated. The expression of high levels of hepatic stem cell markers (TACSTD1, MYC, and hTERT) and low levels of mature hepatocyte markers (UGT2B7 and CYP3A4) indicated that the cells in the hepatospheres might be hepatic stem cells (Supplementary Figure 3A) . The positive immunostaining of hepatic stem markers (AFP and K19) further supported these findings (Supplementary Figure 3B ). Subsequently, tumor formation assays were performed. As few as 2500 ICAM-1 ϩ tumor cells were sufficient to induce tumor formation in nude mice, whereas no tumors were observed after 90 days when equivalent numbers of ICAM-1 Ϫ cells were used (Table 2 and Figure 2B , middle panel). H&E staining confirmed the histologic features of the tumor xenografts ( Figure 2B , right panel). The expression of known liver stem cell markers was also assessed in ICAM-1 ϩ cells from tumor tissues. Except for CD90, which was not observed in the HCC tissues of these 2 patients, most of the results were consistent with those in the tumor cell lines (Supplementary Figure 4) .
Because ICAM-1 expression was previously reported to be correlated with HCC relapse and metastasis, 7 we next sought to determine whether ICAM-1 ϩ tumor cells were present in the blood of patients with HCC. The existence of ICAM-1 ϩ tumor cells was analyzed by flow cytometry. Because ICAM-1 has been reported to be expressed in some lymphocytes, 2 CD45 staining was performed, and CD45 Ϫ ICAM-1 ϩ cells were defined as nonlymphatic ICAM-1 ϩ cells in the blood. 19 As shown in Figure 2C , 0.30% of the cells in a blood sample from a patient with HCC (P#30) were CD45 Ϫ ICAM-1 ϩ cells, whereas no CD45 Ϫ ICAM-1 ϩ cells were detected in the control blood sample (Con). After confirming that the CD45 Ϫ ICAM-1 ϩ cells isolated from the blood of the patient with HCC were hepatocytes (Supplementary Figure 5) , sphere formation and tumor formation assays were performed to investigate whether these cells possessed CSC properties. Isolated CD45 Ϫ ICAM-1 ϩ cells and CD45 Ϫ ICAM-1 Ϫ cells were cultured in serum-free epidermal growth factor/basic fibroblast growth factor-supplemented medium. More hepatospheres were observed among the CD45 Ϫ ICAM-1 ϩ cells than among the CD45 Ϫ ICAM-1 Ϫ cells ( Figure 2D , left panel). To perform the tumor formation assays, CD45 Ϫ ICAM-1 ϩ cells were purified from the blood of patients with HCC via flow cytometry sorting and then injected subcutaneously into nude mice. Three months after the injections, mice injected with 500 circulating CD45 Ϫ ICAM-1 ϩ cells developed tumor nodules, whereas no tumor formation was detected in mice injected with CD45 Ϫ ICAM-1 Ϫ cells (Table 2 and Figure 2D , middle panel). Subsequent H&E staining confirmed that tumor xenografts and tumors induced by CD45 Ϫ ICAM-1 ϩ cells from HCC tumors shared similar histologic features (Figure 2D, right panel) . a Heterogeneous tumor cells, from which the ICAM-1 ϩ and ICAM-1 Ϫ cell subpopulations were sorted, respectively.
BASIC AND TRANSLATIONAL LIVER
Next, the circulating CD45 Ϫ ICAM-1 ϩ tumor cells from 60 patients with HCC were quantified by flow cytometry to determine whether their numbers were correlated with the clinical outcome of patients with HCC. The median CD45 Ϫ ICAM-1 ϩ cell frequency (0.157%) was used as the cutoff value. A total of 30 (50.0%) of the 60 cases exhibited more than 0.157% CD45 Ϫ ICAM-1 ϩ cells in their blood. The correlation of the CD45 Ϫ ICAM-1 ϩ tumor cell frequency with clinicopathologic features is summarized in Table 3 . The frequency of CD45 Ϫ ICAM-1 ϩ cells was . (E) Kaplan-Meier curves for disease-free and overall survival were compared based on the frequency of CD45 Ϫ ICAM-1 ϩ cells in the patients' blood. Patients with a high frequency of CD45 Ϫ ICAM-1 ϩ cells (0.157%) exhibited significantly shorter disease-free survival (P Ͻ .0001, log-rank test) and shorter overall survival (P ϭ .013, log-rank test) than those with a low frequency of CD45 Ϫ ICAM-1 ϩ cells (Ͻ0.157%).
only correlated with age (P ϭ .040, t test). A KaplanMeier survival analysis was then performed using the median CD45 Ϫ ICAM-1 ϩ cell frequency as the cutoff value. Patients with a high CD45 Ϫ ICAM-1 ϩ cell frequency (Ն0.157%) exhibited a significantly shorter disease-free survival period (P Ͻ .0001, log-rank test) and shorter overall survival period (P ϭ .013, log-rank test) than those with a low CD45 Ϫ ICAM-1 ϩ cell frequency (Ͻ0.157%) ( Figure 2E) . A univariate analysis of the CD45 Ϫ ICAM-1 ϩ cell frequency and clinicopathologic factors revealed prognostic significance in all 60 patients. These significant variables (P Ͻ .05) were further entered into a multivariate Cox model, and the results showed that a high frequency of CD45 Ϫ ICAM-1 ϩ cells in the blood of patients with HCC was an independent risk factor for a poor outcome, portal vein tumor thrombus, and ascites (Supplementary Table 3 ). In summary, higher frequencies of CD45 Ϫ ICAM-1 ϩ cells in the blood of patients with HCC correlated with more aggressive tumor behavior and worse clinical outcomes.
Reduction of the Number of ICAM-1 ؉ Cells Inhibits Tumor Incidence and Metastasis In Vivo
Because higher frequencies of CD45 Ϫ ICAM-1 ϩ cells in the blood of patients with HCC correlated with more aggressive tumor behavior and worse clinical outcomes, we next asked whether the inhibition of ICAM-1 in HCC cells would reduce tumor incidence and metastasis in vivo. To reduce ICAM-1 expression specifically in HCC cells, the AFP core promoter was cloned into the plasmid pAFP-ICAM-1-short hairpin RNA (shRNA) to initiate the expression of shRNA targeting ICAM-1 (Supplementary Figure 6A) . After validating the inhibitory effect of pAFP-ICAM-1-shRNA (Sh) on ICAM-1 expression in vitro (Supplementary Figure 6B and C), pAFP-ICAM-1-shRNA and pAFP-ICAM-1-scramble (Sc) were administered to M-TgHBV transgenic mice, which can be used as a model that mimics development of human HCC. 24 Six months later, the frequency of CD45 Ϫ ICAM-1 ϩ cells in the blood of the mice and the frequency of ICAM-1 ϩ HCC cells in their livers were analyzed by flow cytometry. As shown in Figure 3A (upper panel), the frequency of CD45 Ϫ ICAM-1 ϩ cells in the blood of mice treated with Sh was significantly decreased compared with that in the blood of mice treated with Sc (0.12% vs 0.95%, respectively). The proportion of ICAM-1 ϩ HCC cells in the liver was reduced to 0.93% from 3.36% by treatment with Sh ( Figure 3A, lower panel) .
The necropsies performed on all mice that were killed showed that the mice exhibited regional, intrahepatic, and pulmonary metastases. These metastases comprised small visible colonies distributed around local tumors ( Figure  3B ). In the Sh group, 5 of 20 transgenic mice developed HCC tumors, whereas 15 mice were found to exhibit HCC in the Sc group (n ϭ 20). Furthermore, in the Sh group, 3 of 5 mice showed liver metastasis and no lung metastases were found, whereas in the Sc group, all 15 mice with HCC tumors displayed liver metastasis and 53.3% (8/15) of the mice exhibited lung metastasis ( Figure 3C) .
The results show that inhibition of ICAM-1 expression in tumor cells reduced HCC development and metastasis in vivo, which indicates that ICAM-1 could be used as a therapeutic target.
Nanog Directly Regulates ICAM-1 Expression in CSCs
Having documented that ICAM-1 was a potential CSC marker, we sought to elucidate the mechanism regulating ICAM-1 expression in CSCs. Because Sox2, Oct4, and Nanog were reported to have crucial roles in stem cell maintenance and because the ICAM-1 ϩ cells displayed elevated expression of these genes ( Figure 1B ), we performed a bioinformatic analysis to find the binding sites for these transcription factors in the ICAM-1 promoter. As shown in Figure 4A and Supplementary Figure 7A To further test whether ICAM-1 expression was enhanced by Nanog expression, the plasmid pEGFP-nanog containing the human nanog open reading frame was constructed and transfected into Huh7 cells. After validating that Nanog overexpression was induced by pEGFPnanog transfection (Supplementary Figure 8) , ICAM-1 expression was analyzed by real-time PCR. The expression of ICAM-1 was up-regulated approximately 5-fold in the cells transfected with pEGFP-nanog (Nanog) relative to the expression level in cells transfected with the empty pEGFP vector (EGFP) ( Figure 4C, left panel) . Subsequent Western blot analysis validated the increase in ICAM-1 expression induced by overexpression of Nanog at the protein level ( Figure 4C, right panel) . We also determined whether the ICAM-1 expression level could be reduced by inhibiting Nanog expression. We constructed the plasmid pLKO-Sh, which expresses shRNAs targeting human nanog, and the plasmid pLKO-Sc, which was used as a control. Compared with the cells transfected with Sc, ICAM-1 expression was significantly reduced at both the mRNA and protein levels in cells transfected with Sh ( Figure 4D ). Next, immunofluorescence staining was performed to validate the colocalization of Nanog and ICAM-1 in spheres from tumor cell lines. Double immunofluorescence staining showed that ICAM-1 (red) was located near Nanog (green), which localized to the nuclei of the cells ( Figure 4E ). Furthermore, flow cytometry analysis showed the existence of Nanog ϩ ICAM-1 ϩ tumor cells in tumor samples and blood samples from patients with HCC, indicating that Nanog and ICAM-1 are coexpressed in tumor cells in vivo ( Figure 4F) .
Collectively, these results indicate that ICAM-1 expression is directly transcribed by Nanog in CSCs enriched through sphere formation assays.
Discussion
In this study, we showed that ICAM-1 ϩ cells isolated from cell lines and clinical samples were capable of inducing tumors in vivo and forming spheres in vitro, indicating that the ICAM-1 ϩ cells exhibited CSC properties and that ICAM-1 could be used as a potential marker for CSCs. The specific inhibition of ICAM-1 expression in vivo reduced HCC development and metastasis, which indicated that ICAM-1 could be used as a therapeutic target. Moreover, ICAM-1 was found to be transcribed directly by Nanog in CSCs. Because ICAM-1, identified as a CSC marker, was found to be regulated by Nanog under our experimental conditions, ICAM-1 ϩ tumor cells may represent CSCs with a phenotype involving Nanog expression. Emerging studies have detected the general expression of stemness-related genes, including nanog, in CSCs isolated based on their expression of various surface molecules. 19, 25 In these reports, the expression of stemness-related genes was used to characterize the CSC properties of tumor cells positive for the expression of potential CSC markers. Little has been reported about the relationship of these potential CSC markers with the expressed stemness-related genes except that CD24 activated the Nanog promoter in a STAT3-dependent manner. 25 In addition, the fact that even CSCs isolated from the same tumor can express several different surface markers and exhibit distinct cellular behaviors indicates that tumors may contain distinct subpopulations of CSCs. 26 In this study, we found that the expression of ICAM-1, a potential CSC marker, was transcribed by Nanog in tumor cells (Figure 4) . Because of the crucial role of Nanog in maintaining stem cells, ICAM-1 ϩ tumor cells may represent the primary CSC subpopulation. In the present study, ICAM-1 expression in HCC cells overlapped with the expression of reported HCC CSC markers, such as CD24, CD44, CD90, CD133, and EpCAM ( Supplementary Figures 1 and 4) , and ICAM-1 ϩ tumor cells also expressed hepatic stem cell markers (AFP, K19) ( Supplementary Figures 2 and 5) . These data further suggest that ICAM-1 ϩ tumor cells may generate heterogeneous subpopulations that display stem/progenitor cell features and express other reported CSC markers. Under our experimental condition, however, very few ICAM-1 ϩ cells expressed NCAM, a potential biomarker for liver cancers, 27 which indicates that ICAM-1 cannot be used as a marker for all CSCs in liver cancer. Additionally, the specific inhibition of ICAM-1 expression in HCC cells in vivo reduced tumor development and metastasis, indicating that ICAM-1 could be used as a therapeutic target. The expression of ICAM-1 in CSCs from other types of tumors should be analyzed; we plan to address this question in the future.
Finding CD45 Ϫ ICAM-1 ϩ cells in the blood of patients with HCC provided support for the existence of circulating tumor cells (CTCs) and suggested that CTCs also possess CSC properties. CTCs, which possess the antigenic and/or genetic characteristics of a specific tumor type, have been found in the blood of patients with different types of tumors, including breast cancer, colorectal cancer, and lung cancer. Emerging evidence has shown a correlation between CTCs and patient prognosis. 28 Consistent with previous studies, we detected Ͻ0.5% CD45 Ϫ ICAM-1 ϩ tumor cells in patients' blood and none in the blood from healthy subjects ( Figure 2C ). Furthermore, statistical analysis showed that the frequency of CD45 Ϫ ICAM-1 ϩ cells correlated with patient prognosis ( Figure 2E ). In addition, CTCs were found to express different genes than primary tumor cells and to possess a metastatic nature. 29, 30 In the present study, we found that CD45 Ϫ ICAM-1 ϩ circulating cells exhibit tumor induction and sphere-forming capacities, indicating that the circulating tumor cells may possess CSC properties. Yang et al also reported that tumor cells detected in the blood based on their expression of the surface molecules CD90 and CD44 display CSC properties. 19 The CSC theory suggests that this result might be attributable to the significant genetic and phenotypic heterogeneity of CTCs. Additionally, the mesenchymal characteristics of CD45 Ϫ ICAM-1 ϩ cells (E-cadherin Ϫ /Vimentin ϩ ; Supplementary Figure 9 ) further suggested that this subpopulation in the blood of patients with HCC possessed CSC properties and supported the potential relationship between the frequency of these cells and a poor prognosis.
Although ICAM-1 ϩ CSCs have been shown to play a crucial role in hepatocarcinogenesis, our study also raises many critical questions. How is ICAM-1 expression regulated in tumor cells? What are the ICAM-1-mediated signaling networks in CSCs? How do we exclude the possibility that these are stellate cell precursors that express ICAM-1 31 ? Comprehensive investigation will be helpful in revealing the mechanisms involved in the maintenance of ICAM-1 ϩ liver CSCs. In addition, although transcription factors including Nanog and Oct4 are known to be crucial for embryonic stem cell self-renewal and have been shown to contribute much to tumorigen- esis, [32] [33] [34] little is known about the underlying mechanisms. It should be noted that Nanog is derived from a transcribed pseudogene (NANOGP8) in tumor cells, not from NANOGP1 as in ES cells. This indicates that a distinct network mediated by Nanog might be involved in tumorigenesis. The investigation of the pathways and molecules associated with Nanog in CSCs is necessary to reveal the regulatory circuitry of CSCs. Much of this work is in progress in our laboratory.
In summary, we identified ICAM-1 as a CSC marker regulated by Nanog, which is generally expressed in CSCs in HCC. Our investigation showed the presence of ICAM-1 ϩ CSCs in HCC cell lines and clinical samples. Cohort analysis confirmed the relevance of circulating ICAM-1 ϩ cells for the prognosis and survival of patients with HCC. Our results indicate that ICAM-1 can be used as a potential CSC marker and may therefore be helpful in developing an effective treatment against cancer. Supplementary 
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